http://purl.org/np/RAu1XyKMbx... RAu1XyKMbx

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-11T07:48:16.935Z

http://purl.org/np/RAu1XyKMbx... RAu1XyKMbx

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-11T07:48:16.935632

Elif Ozkan

2022-10-11T07:48:16.935Z

http://purl.org/np/RAu1XyKMbx... RAu1XyKMbx

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

Adalimumab is indicated to treat the following conditions: moderately to severely active rheumatoid arthritis in adults. Crohn's disease in patients 6 years of age and older. Moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate, as well as those with systemic therapy are less likely to benefit from phototherapy.

Elif Ozkan

2022-10-11T07:48:16.935Z